Approval · Notice of Compliance 36837 · 2026
BRILINTA: Notice of Compliance 36837
Issued February 3, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36837
- Date
- February 3, 2026
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Product Monograph reformatted to the Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BRILINTA | Not yet assigned | — |
Medicinal ingredients
- TICAGRELOR 60 MG per TAB
- TICAGRELOR 90 MG per TAB